• Disc Medicine will present portfolio data at the American Society of Hematology annual meeting in New Orleans, December 12-15, 2026.
• Clinical updates will include Phase 2 results for selcodebart in myelofibrosis-related anemia and DISC-3405 in polycythemia vera.
• Initial Phase 1b results for DISC-3405 in sickle cell disease will also be presented.
• Bitopertin-related preclinical findings showed reduced chronic inflammation and improved red blood cell health in a mouse model of erythropoietic protoporphyria.
• Published clinical abstracts contain previously presented data; new results and analyses are reserved for the conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040905PRIMZONEFULLFEED9869728) on November 04, 2026, and is solely responsible for the information contained therein.